Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -56.13% is 152% below its 5-year average of -22.30%, around the middle of its 5-year range (-206.43%–132.30%).
As of the fiscal period ended Monday, June 30, 2025. 35.83% below its 12-month average of -41.33%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
-56.13%
RETURN ON EQUITY (ROE) AVG TTM
-41.33%
RETURN ON EQUITY (ROE) AVG 3Y
9.62%
RETURN ON EQUITY (ROE) AVG 5Y
-22.30%
RETURN ON EQUITY (ROE) AVG 10Y
-4.36%
RETURN ON EQUITY (ROE) AVG 15Y
11.68%
RETURN ON EQUITY (ROE) AVG 20Y
15.21%
CURRENT VS TTM AVG
-35.83%
CURRENT VS 3Y AVG
-683.32%
CURRENT VS 5Y AVG
-151.67%
CURRENT VS 10Y AVG
-1187.92%
CURRENT VS 15Y AVG
-580.63%
CURRENT VS 20Y AVG
-469.10%
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-615.43%
vs the sector median at left
Cardinal Health, Inc.
Market Cap
$53.66B
Return on Equity (ROE)
-56.13%
TTM Avg
-41.33%
3Y Avg
9.62%
5Y Avg
-22.30%
Market Cap
$49.38B
Return on Equity (ROE)
10.58%
TTM Avg
26.07%
3Y Avg
24.86%
5Y Avg
23.86%
Market Cap
$61.01B
Return on Equity (ROE)
4.72%
TTM Avg
6.60%
3Y Avg
6.50%
5Y Avg
6.42%
Market Cap
$61.99B
Return on Equity (ROE)
75.01%
TTM Avg
168.34%
3Y Avg
-32.99%
5Y Avg
148.52%
Market Cap
$44.95B
Return on Equity (ROE)
70.38%
TTM Avg
60.82%
3Y Avg
72.53%
5Y Avg
81.69%
Market Cap
$43.93B
Return on Equity (ROE)
6.66%
TTM Avg
7.05%
3Y Avg
11.93%
5Y Avg
15.09%
Market Cap
$41.35B
Return on Equity (ROE)
22.28%
TTM Avg
21.77%
3Y Avg
21.17%
5Y Avg
17.55%
Market Cap
$39.63B
Return on Equity (ROE)
19.85%
TTM Avg
20.59%
3Y Avg
21.51%
5Y Avg
20.54%
Market Cap
$68.43B
Return on Equity (ROE)
14.19%
TTM Avg
10.21%
3Y Avg
8.16%
5Y Avg
6.40%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cardinal Health, Inc. (CAH) | $53.66B | -56.13% | -41.33% | 9.62% | -22.30% |
| Edwards Lifesciences Corporation (EW)vs › | $49.38B | 10.58% | 26.07% | 24.86% | 23.86% |
| Becton, Dickinson and Company (BDX)vs › | $61.01B | 4.72% | 6.60% | 6.50% | 6.42% |
| Cencora, Inc. (COR)vs › | $61.99B | 75.01% | 168.34% | -32.99% | 148.52% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $44.95B | 70.38% | 60.82% | 72.53% | 81.69% |
| Humana Inc. (HUM)vs › | $43.93B | 6.66% | 7.05% | 11.93% | 15.09% |
| IQVIA Holdings Inc. (IQV)vs › | $41.35B | 22.28% | 21.77% | 21.17% | 17.55% |
| Agilent Technologies, Inc. (A)vs › | $39.63B | 19.85% | 20.59% | 21.51% | 20.54% |
| Boston Scientific Corporation (BSX)vs › | $68.43B | 14.19% | 10.21% | 8.16% | 6.40% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $38.27B | 53.68% | -187.43% | 134.89% | 51.69% |
ROE
-56.1%
ROA
2.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-06-30 | -56.13% |
| 2024-06-30 | -26.52% |
| 2023-06-30 | -11.16% |
| 2022-06-30 | 132.30% |
| 2021-06-30 | 34.12% |
| 2020-06-30 | -206.43% |
| 2019-06-30 | 21.54% |
| 2018-06-30 | 4.23% |
| 2017-06-30 | 18.92% |
| 2016-06-30 | 21.77% |
| 2015-06-30 | 19.42% |
| 2014-06-30 | 18.22% |
| 2013-06-30 | 5.59% |
| 2012-06-30 | 17.12% |
| 2011-06-30 | 16.40% |
| 2010-06-30 | 12.17% |
| 2009-06-30 | 13.20% |
| 2008-06-30 | 16.79% |
| 2007-06-30 | 26.18% |
| 2006-06-30 | 11.78% |
| 2005-06-30 | 12.23% |
| 2004-06-30 | 18.49% |
| 2003-06-30 | 18.32% |
| 2002-06-30 | 16.52% |
| 2001-06-30 | 15.77% |
| 2000-06-30 | 15.45% |
| 1999-06-30 | 12.78% |
| 1998-06-30 | 8.36% |
| 1997-06-30 | 13.57% |
| 1996-06-30 | 10.80% |
